Redeye comments on EG7 Q1-results which saw strong topline while EBITDA was somewhat softer than exp...
Redeye is bullish about the new results with BI-1808 in cutaneous T-cell lymphoma.
Redeye updates its estimates following Surgical Science’s Q1 2025 report, which beat our projections...
Redeye updates on Gentoo Media after weaker-than-expected Q1-results where the regulation of online ...
Weak Q1 top line, rapid actions taken We cut '25e-'26e adj.
Internal efficiency development to continue 34% adj.
CEO highlighted importance of product innovation New Bangladesh factory remains core part of strateg...
Well-positioned in a growing market Reducing SKU's and suppliers to improve profitability Expect mar...
Director Group Finance emphasised recent milestones.
Several growth drivers from product innovation and portfolio expansion Quarterly volatility is part ...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) har nyligen rapporterat årets f...
CirChem (”CirChem” eller ”Bolaget”) har publicerat Bolagets delårsrapport för det första kvartalet 2...
Q1 confirms that Terclara defends a leading market position in Sweden and that the Norwegian launch ...
Redeye provides an update on Acarix following its Q1 report, which showed continued growth in revenu...
Q1 was an active quarter for Cantargia. Among other things, positive multiple ascending dose results...
Med en framgångsrik företrädesemission i ryggen, som tillförde AcuCort AB (”AcuCort” eller ”Bolaget”...
Irisity AB (”Irisity” or ”the Company”) published its Q1 report for 2025 on the 13th of May 2025.
Q1 sales 20% below cons, partly driven by Brazil impact Adj.
Redeye provides an initial take following the release of SenzaGen’s Q1 2025 report.
Redeye comments on Gentoo Media’s Q1-results which were lower than expected owing to a larger than a...